title: Tumor-specific T-cell help is associated with improved survival in melanoma.
abstract: Despite success with immune checkpoint inhibitors, clinical benefit from cancer vaccines remains elusive. Combined targeting of melanoma-specific CD4(+) and CD8(+) T-lymphocyte epitopes was associated with improved survival compared with targeting either alone, or when a nonspecific helper epitope was used. We discuss the potential role of antigen-specific CD4 help.
authors.affiliation: Ludwig Institute for Cancer Research Melbourne-Austin Branch, Heidelberg, Australia.
authors.forename: Katherine
authors.initials: K
authors.lastname: Woods
authors.forename: Jonathan
authors.initials: J
authors.lastname: Cebon
mesh_terms: D015704:CD4 Antigens / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes; D018414:CD8-Positive T-Lymphocytes; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D005434:Flow Cytometry; D006801:Humans; D007167:Immunotherapy; D008213:Lymphocyte Activation / Q000276:immunology; D008545:Melanoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D016019:Survival Analysis
chemical_list: D015704:CD4 Antigens; D019496:Cancer Vaccines; D018984:Epitopes, T-Lymphocyte